Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti... see more

Current News (NDAQ:BYSI)

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

GlobeNewswire 12 hours ago

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

GlobeNewswire March 30, 2026

BeyondSpring Files 2025 Annual Report on Form 10-K

GlobeNewswire March 25, 2026

BeyondSpring Reports 2025 Year-End Financial Results

GlobeNewswire March 25, 2026

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

GlobeNewswire February 9, 2026

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

GlobeNewswire December 12, 2025

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

GlobeNewswire December 11, 2025

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

GlobeNewswire August 13, 2025
View More News ››

Opinion & Analysis (NDAQ:BYSI)

Biotech advances potential 'billion-dollar drug' with new trial launch in China

Streetwise Reports December 8, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BYSI)

RE:REAL DEAL

From last quarterly report:  "As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of ...
dmacd - March 14, 2022

RE:Compelling despite Headwinds

Well if it goes to $3/sh or cash valuation then it is time for me to double down. I did not think that chance would come. The market is...
dmacd - January 19, 2022

Compelling despite Headwinds

$90M cash vs $128M MC. Way too low for a company this advanced. FDA caused job losses in US with their approach. Would be nice to get...
dmacd - January 12, 2022

RE:REAL DEAL

Blockbuster is probable. Strongest terms with a Chinese entity I have seen in quite some time for an emerging player. $45M cash up front...
dmacd - August 26, 2021

REAL DEAL

disruptive lung cancer treatment on verge of FDA approval
Felix12345 - August 23, 2021
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp., an exploration stage company, acquires, explores, and develops natural resource properties ...
View More »

Podcasts